Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Isr Med Assoc J. 2022 Jan;24(1):9-10.

Abstract

The Oxford-AstraZeneca vaccine ChAdOx1 (AZD1222, Vaxzevria) is playing a crucial role in counteracting the coronavirus disease-2019 (COVID-19) pandemic [1]. Since March 2021, reports of unexpected thrombotic events associated with thrombocytopenia and vaccination have been published [2]. To the best of our knowledge there is only one report about vaccination-associated myasthenia gravis (MG) occurring after a second dose of BNT162b2 (Pfizer-BioNTech).

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / adverse effects
  • COVID-19 Vaccines / immunology
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • ChAdOx1 nCoV-19* / administration & dosage
  • ChAdOx1 nCoV-19* / adverse effects
  • ChAdOx1 nCoV-19* / immunology
  • Cholinesterase Inhibitors / administration & dosage
  • Diagnosis, Differential
  • Drug-Related Side Effects and Adverse Reactions / diagnosis*
  • Drug-Related Side Effects and Adverse Reactions / etiology
  • Drug-Related Side Effects and Adverse Reactions / immunology
  • Fever / etiology
  • Fever / therapy
  • Humans
  • Male
  • Myalgia / etiology
  • Myalgia / therapy
  • Myasthenia Gravis* / diagnosis
  • Myasthenia Gravis* / drug therapy
  • Myasthenia Gravis* / immunology
  • Myasthenia Gravis* / physiopathology
  • Pyridostigmine Bromide / administration & dosage*
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • COVID-19 Vaccines
  • Cholinesterase Inhibitors
  • ChAdOx1 nCoV-19
  • Pyridostigmine Bromide